Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma

• Verfasst von: Freyschlag, Christian F. [VerfasserIn]
• Verfasst von: Tüttenberg, Jochen [VerfasserIn]
• Verfasst von: Lohr, Frank [VerfasserIn]
• Verfasst von: Thomé, Claudius [VerfasserIn]
• Verfasst von: Schmieder, Kirsten [VerfasserIn]
• Verfasst von: Seiz-Rosenhagen, Marcel [VerfasserIn]
• Titel: Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma
• Verf.angabe: C.F. Freyschlag, J. Tuettenberg, F. Lohr, C. Thomé, K. Schmieder and M. Seiz
• E-Jahr: 2011
• Jahr: April 15, 2011
• Umfang: 3 S.
• Fussnoten: Gesehen am 10.05.2023
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2011
• Band/Heft Quelle: 31(2011), 3 vom: März, Seite 1023-1025
• ISSN Quelle: 1791-7530
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Anaplastic ependymoma
• Sach-SW: multifocal recurrence
• Sach-SW: temozolomide
• K10plus-PPN: 1844961982

Abstract

Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms. Thus, no standard adjuvant therapy after surgical resection has been defined so far. External radiotherapy is commonly administered, but the role of chemotherapy is still unclear in malignant ependymomas. The case of a 25-year-old female patient with multifocal recurrence of a supratentorial malignant ependymoma administered temozolomide as second-line therapy is reported. Currently, 5 months after initiation of temozolomide treatment, there is no evidence of radiographic progression. Temozolomide could constitute a promising approach to supratentorial recurrent and multifocal anaplastic ependymoma of adults.